Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neumora Therapeutics, Inc. (NMRA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Neumora uses current reports on Form 8-K and other filings to communicate material information about its financial condition, capital structure and key pipeline events.
In recent 8-K filings, Neumora has reported quarterly financial results, including details on research and development and general and administrative expenses, net loss and cash, cash equivalents and marketable securities. These filings also reference the company’s expectation that its available capital will fund its operating plan into 2027, based on the specific reporting dates. Other 8-Ks describe business updates such as the initiation of a Phase 1 SAD/MAD study of NMRA-898, a positive preclinical data announcement for NMRA-215, and the associated press releases furnished or filed as exhibits.
Neumora has also filed an 8-K describing a conversion under its Loan and Security Agreement with K2 HealthVentures LLC, in which a portion of the outstanding term loan principal was converted into shares of common stock. This filing outlines the conversion terms, the number of shares issued and the reliance on a registration exemption under the Securities Act of 1933.
On Stock Titan, Neumora’s SEC filings are updated as they appear on EDGAR, and AI-powered summaries help explain the key points in plain language. Users can review current reports on Form 8-K for material events, track changes related to financing arrangements, and connect these disclosures with the company’s broader clinical and business narrative. This page is a resource for understanding how Neumora reports its financial results, capital transactions and significant pipeline milestones to regulators and investors.
Neumora Therapeutics, Inc. has a planned sale notice under Rule 144 covering 9,819 shares of common stock. The shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $34,458.98 and an approximate sale date of February 17, 2026.
The securities were acquired on February 14, 2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
Neumora Therapeutics (NMRA) had a security holder file a notice of proposed sale of 6,165 shares of common stock under Rule 144. The planned sale, through Merrill Lynch on NASDAQ around 02/17/2026, had an aggregate market value of $21,916.58 at the time of the notice.
The shares come from a restricted stock unit award that vested on 02/14/2026 and was granted as part of the issuer’s equity compensation plan. Neumora had 167,089,114 shares of common stock outstanding, which is a baseline figure for the company’s total equity.
Neumora Therapeutics, Inc. is the issuer for a planned sale of restricted shares under Rule 144. The notice covers the proposed sale of 1,436 shares of common stock through Merrill Lynch on or around 02/17/2026 on the NASDAQ market, with an aggregate market value of $5,119.34. These shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan. The filing notes that 167,089,114 shares of common stock were outstanding at the time referenced.
Neumora Therapeutics furnished a corporate presentation for use at the Guggenheim Emerging Outlook: Biotech Summit, highlighting Phase 1b data for NMRA-511 in agitation associated with Alzheimer’s disease. The randomized, double-blind study enrolled 40 patients on NMRA-511 and 40 on placebo over eight weeks, plus a small healthy-elderly cohort.
In a pre-specified elevated anxiety subgroup, NMRA-511 showed Cohen’s d effect sizes of 0.51–0.64 on the CMAI agitation scale, up to 0.78 on CGI-S agitation, and 0.42–0.46 on the NPI agitation/aggression domain, with nominal p-values down to <0.05. Treatment-emergent adverse events were generally mild to moderate, discontinuations due to side effects were 2.5%, and one serious adverse event resolved fully. The company notes potential for higher dosing and future studies that enrich for patients with elevated anxiety.
Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The presentation, dated January 2026, is provided as Exhibit 99.1 to this report and is incorporated into the report by reference.
The company notes that the presentation and related information are being furnished, not filed, which means they are not subject to certain liability provisions under federal securities laws and will not automatically be incorporated into other SEC documents.
Neumora Therapeutics, Inc. reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option covering 350,000 shares of common stock on January 8, 2026. The option has an exercise price of $2.33 per share and is held directly. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported a Form 4 transaction for officer Daljit Singh Aurora, its Chief Operating and Development Officer. On January 8, 2026, Aurora received a stock option to buy 750,000 shares of common stock at an exercise price of $2.33 per share, with no cost reported for the option itself.
All 750,000 derivative securities are shown as beneficially owned directly after the grant. The option vests over four years: 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the option is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026. These options give him the right to buy those shares at an exercise price of $2.33 per share. The grant was reported as a direct beneficial ownership position, with 750,000 derivative securities held after the transaction.
According to the vesting terms, 25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years. This structure means the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date, aligning the officer’s potential equity ownership with longer-term service to the company.
Neumora Therapeutics, Inc. reported a new equity award for President Joshua PintoJanuary 8, 2026, he was granted an option to purchase 1,200,000 shares of common stock at an exercise price of $2.33 per share. According to the vesting terms, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
Neumora Therapeutics, Inc. reported that Chief Executive Officer and Chairman of the Board Paul L. Berns received a grant of stock options on January 8, 2026. The Form 4 shows an award of 1,650,000 stock options, each with an exercise price of $2.33 per share, giving him the right to buy common stock at that price. The options were acquired as a derivative security and are held directly, with 1,650,000 derivative securities beneficially owned following the transaction.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the entire grant is fully vested and exercisable on the fourth anniversary of that date.